Skip to main content Skip to main navigation menu Skip to site footer
Confinia Cephalalgica

eISSN 3035-0670 | Official journal of the Italian Society for the Study of Headaches (SISC)

  • About the Journal
  • Publication Ethics
  • Editorial Board
  • Current
  • Archives
  • Copyright
  • Register
  • Login
  • Search
  • Contacts
  • News

Editor-in-Chief: Pierangelo Geppetti, Italy

0.5
CiteScore 2024
0.5
CiteScore 2024
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • PO-08 | Long-term outcome in pediatric patients with headache S. Genta,1,2 M. Celario1,2, C. Brancaccio¹ ², G. Rossetto,1,2 C. Dusi,1,2 P. Baso,1,2 V. De Giorgis1,2 | 1Department of Child Neuropsychiatry, IRCCS Mondino, Pavia; 2University of Pavia, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15829
    202
  • OC-13 | Monoclonal antibodies targeting CGRP differently affect sleep and psychiatric comorbidities in reproductive and postmenopausal chronic migraine women Giulia Procopio, Letizia Curto, Antonia Di Chirico, Leonardo Troilo, Gabriele Siciliano, Filippo Baldacci, Sara Gori | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15810
    277
  • Kinetic oscillation stimulation for the preventive treatment of refractory chronic migraine: a case series

    Giorgio Liaci, Claudia Altamura, Nicoletta Brunelli, Alessandro Alesina, Luisa Fofi, Maria Pia Prudenzano, Fabrizio Vernieri
    02-01-2025
    https://doi.org/10.4081/cc.2024.15776
    1141
    PDF: 217
  • PO-78 | No changes in blood pressure assessed with the 24-hour Holter monitoring in patients treated with anti-CGRP monoclonal antibodies: a prospective observational study (SAFHYPER) Flavia Lo Castro,1 Niccolò Bonini,2 Luigi Francesco Iannone,1,3 Alberto Boccalini,1 Daria Brovia,1 Luca Pani,1,3 Giuseppe Boriani,2,3 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Cardiology Division, AOU Policlinico di Modena, Modena, Italy; 3Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15902
    209
  • OC-04 | The chronopharmacology of atogepant in migraine prevention: a real-world evaluation of influence of timing of administration on effectiveness and tolerability Luigi Francesco Iannone,1,2 Gabriele Sebastianelli,3 Flavia Lo Castro,2 Federico De Santis,4 Michele Corrado,5 Marilena Marcosano,6,7 Raffaele Ornello,4 Licia Grazzi,8 Danilo Antonio Montisano,8 Francesco De Cesaris,9 Antonio Munafò,9 Gianluca Avino,10 Michele Trimboli,11 Maria Albanese,12 Antonio Russo,13 Giorgio Dalla Volta,14 Marina Romozzi,15 Paola Merlo,16 Luisa Fofi,6,7 Alberto Doretti,17 Gloria Vaghi,5 Francesca Pistoia,4 Delfina Ferrandi,18 Stefania Battistini,19 Gianluca Coppola,3 Simona Sacco,4 Simona Guerzoni,2 Claudia Altamura,6,7 Fabrizio Vernieri,6,7 On behalf of the Italian Headache Registry (RICe) Study Group | 1Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia; 2Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena; 3Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina; 4Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 5Department of Brain and Behavioral Sciences, University of Pavia; Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia; 6Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma; 7Neurology Unit, Università Campus Bio-Medico di Roma; 8Neuroalgology Unit and Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; 9Headache center and Clinical Pharmacology, AOU Careggi, Florence; 10SOC Neurologia, Ospedale di Prato; 11Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 12Università Roma Tor Vergata, Roma; 13Università della Campania "Luigi Vanvitelli", Napoli; 14U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia; 15Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 16UO di Neurologia, Humanitas Gavazzeni, Bergamo; 17Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano; 18Neurology Department, Azienda Ospedaliero Universitaria, Santi Antonio e Biagio e Cesare Arrigo, Alessandria; 19Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15801
    107
  • PO-42 | OnaBotulinumtoxin-A in chronic migraine patients with short or long disease history and psychiatric comorbidities: preliminary data from an Italian multicentric study (the BACH Study) Fabrizio Vernieri,1,2 Marilena Marcosano,2 Licia Grazzi,3 Danilo Antonio Montisano,3 Raffaele Ornello,4 Simona Sacco,4 Chiara Rosignoli,4 Alberto Doretti,5 Maria Albanese,6 Giovanna Viticchi,7 Nicoletta Brunelli, Luigi d’Onofrio,2 Luisa Fofi,1 Claudia Altamura,1,2 Patrizio Pasqualetti8 | 1Fondazione Policlinico Campus Bio-Medico, Roma, Italy; 2Università Campus Bio-Medico di Roma, Italy; 3Istituto Neurologico Besta, Milano, Italy; 4Università degli Studi l’Aquila, Italy; 5Istituto Auxologico, Milano, Italy; 6Policlinico Tor Vergata, Roma, Italy; 7Università Politecnica Marche, Italy; 8Sapienza Università di Roma, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15864
    143
  • Plasma CGRP but not PACAP-38 concentrations are associated with response to anti-CGRP monoclonal antibodies in migraine

    Elisa Rubino, Andrea Marcinnò, Silvia Boschi, Elisa Maria Piella, Alberto Mario Chiarandon, Fausto Roveta, Erica Gallo, Innocenzo Rainero
    26-11-2025
    https://doi.org/10.4081/cc.2025.15790
    186
    PDF: 61
  • PO-40 | Evaluating agreement between physician and ChatGPT in migraine prophylaxis selection: a pilot comparative study Simone Vigneri1, MatteoZanella2, Gianfranco Sindaco2, Alberto Merlin2, Maria Mazzullo2, Marco La Grua2, Valentina Paci2, Carmen Bertone2, Gilberto Pari2 1Santa Maria Maddalena Hospital, Neurology, Occhiobello, Italy; 2Santa Maria Maddalena Hospital, Pain Medicine, Occhiobello, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15862
    170
  • Anti-CGRP monoclonal antibodies and migraine with aura: a narrative review

    Danilo Antonio Montisano, Marcella De Luca, Sara Giannoni, Giada Giuliani, Marilena Marcosano, Antonio Munafò, Daniele Pala, Federica Pes, Marina Romozzi, Gabriele Sebastianelli
    12-09-2025
    https://doi.org/10.4081/cc.2025.15789
    756
    PDF: 244
  • PO-31 | Could lamotrigine represent an effective treatment strategy in patients with migraine with aura? An observational study M. Marziani, M. Silvestro, I. Orologio, L. Tartaglione, F.M. Chianese, A. Tessitore, A. Russo | Headache Centre, Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15853
    294
  • Efficacy and safety of greater occipital nerve block with a small volume of lidocaine and methylprednisolone in tertiary headache center

    Chiara Rosignoli, Agnese Onofri, Federico De Santis, Simona Sacco, Raffaele Ornello
    09-07-2024
    https://doi.org/10.4081/cc.2024.15770
    4156
    PDF: 388
  • PO-28 | Sex differences in the response to rimegepant for the treatment of acute migraine attacks – insights from the multicenter GAINER study Raffaele Ornello,1 Gloria Vaghi,2,3 Gabriele Sebastianelli,4 Francesco Casillo,4 Antonio Russo,5 Marcello Silvestro,5 Francesca Pistoia,1 Giorgio Dalla Volta,6 Matteo Cortinovis,6 Alberto Chiarugi,7 Danilo Antonio Montisano,8 Licia Grazzi,8 Maria Pia Prudenzano,9 Sabina Cevoli,10 Edoardo Mampreso,11 Gianluca Avino,12 Marina Romozzi,13 Mariarosaria Valente,14 Carla Fasano,15 Stefania Battistini,16 Antonio Granato,17 Elisa Maria Piella,18 Innocenzo Rainero,18 Federico De Santis,1 Simona Sacco,1 Maria Albanese,19 Michele Trimboli,20 Alberto Doretti,21 Cristina Tassorelli,2,3 Luigi Francesco Iannone,22 Roberto De Icco2,3 on behalf of the Italian Headache Registry (RICe) Study Group | 1Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 2Department of Brain and Behavioral Sciences, University of Pavia; 3Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia; 4Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina; 5Headache Centre, Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples; 6Headache Center of Clinical Neurology of Istituto Clinico "Città di Brescia", Brescia; 7Department of Health Sciences, University of Florence; 8Neuroalgology Unit and Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; 9Headache Center, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari; 10IRCCS Istituto Di Scienze Neurologiche di Bologna, Programma Cefalee e Algie Facciali, Bologna; 11Headache Centre, Neurology - Euganea, Health Unit, Padua; 12Neurology Unit, Ospedale Santo Stefano, USL Toscana Centro, Prato; 13Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome; 14Clinical Neurology, Azienda Sanitaria Universitaria Friuli Centrale, Presidio Ospedaliero Santa Maria della Misericordia, Udine; 15Headache and Facial Pain Center Neurology, AOU Careggi, Florence; 16Department of Medical, Surgical and Neurological Sciences, University of Siena; 17Headache Centre, Clinical Unit of Neurology, School of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste, ASUGI, University of Trieste; 18Department of Neurosciences “Rita Levi Montalcini”, University of Turin; 19Department of Systems Medicine, University of Rome Tor Vergata, Rome; 20University Magna Graecia, Catanzaro; 21Department of Neuroscience - Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan; 22University of Modena and Reggio Emilia, Modena, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15850
    222
1 - 12 of 12 items

authors

FOR AUTHORS
  • SUBMIT YOUR PAPER
  • Guide for Authors
  • Benefits for Authors
  • How to write a scientific paper
  • How to write a Review article

reviewers

FOR REVIEWERS
  • Benefits for Reviewers
  • How to review

Categories

    • Newsletter
    • 39° Conference of the Italian Society for the Study of Headaches (SISC)
    • SISC-Oral Communications
    • SISC-Posters

indexing

INDEXING
  • Scopus
  • OpenAlex
  • Analytics

Keywords

Confinia Cephalalgica

is an Open Access, peer-reviewed journal published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS. eISSN 3035-0670 (Website continuously updated).

pISSN: 1122-0279
eISSN: 3035-0670

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission
  • Guidelines For Authors

Our App Is Free For Anyone!

Themes by Openjournaltheme.com

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185    •    Privacy